Followers | 46 |
Posts | 4449 |
Boards Moderated | 0 |
Alias Born | 07/26/2010 |
Saturday, September 19, 2020 1:06:04 PM
https://twitter.com/PattesonLab/status/1303735403061669888/photo/1
9/6/20 - 5 Conclusion
The striking viscoelastic properties of VIF networks in vitro suggest cellular functions based on resistance to mechanical stress and regulation of cell shape. Indeed VIFs are essential for protection of the nucleus from potentially damaging forces and forms much of the cytoskeleton. However, many studies point to important non-mechanical functions. Vimentin, either in the form of small oligomers or VIFs, binds numerous proteins and nucleic acids, and functions to integrate with other cytoskeletal systems, regulate lipid metabolism and perform numerous other intracellular functions. In addition, the rapidly growing study of extracellular vimentin, especially in the regulated disassembly of VIF and the secretion of modified vimentin, reveals many new functions for the protein, from mediating pathogen invasion to promoting wound healing. Clearly there is much more to be learned about this abundant but understudied protein.
https://onlinelibrary.wiley.com/doi/full/10.1002/bies.202000078
Recent NBIO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 06:46:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 06:45:51 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 07:06:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 01:00:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 07:47:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/09/2023 07:22:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/09/2023 07:21:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2023 05:54:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/18/2023 09:00:29 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:00:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/14/2023 06:37:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/14/2023 12:42:59 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 07/03/2023 09:15:17 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/29/2023 04:26:16 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM